Consistent with this observation that MEK/ERK signaling is implicated in PD-related pathological alterations, pharmacological inhibition of MEK1/2 kinase activity rescued the inflammatory profile of LRRK2 G2019S astrocytes and attenuated cytokine secretion (Fig. 5). The gene discussed is MAP2K7; the disease is Parkinson disease.